EZH1 and T-cell non-Hodgkin lymphoma: In this study, we evaluated the EZH1/2 mutation status in a cohort of 33 MEITL by NGS and investigated the immunohistochemical protein expression of EZH1, EZH2, and H3K27me3 in combination with the clinical outcomes in 46 patients with T-cell lymphomas.